sprite-preloader
Anzeige
Mehr »
Samstag, 16.12.2017 Börsentäglich über 12.000 News von 575 internationalen Medien

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Devisen

Kurs

%

Rohstoffe

Kurs

%

Passende Knock-Outs zu Ihrer Suchanfrage (Anzeige)
Erweiterte
Suche
lynx
Ad hoc-Mitteilungen

Aktuelle News von BioPharma-Reporter

  • 24 h
  • letzte 200 News
ZeitAktuelle Nachrichten
FrBig batches, big margins: Reneuron on off-the-shelf stem cells
FrCMC Biologics to make Harpoon's cancer drugs in Seattle, US
FrLilly to pump $1.2bn into its biomanufacturing in 2018
FrTeva picks Beacon, brings antibody development to light in Australia
DoPfizer: 'No plans to launch second approved Remicade biosimilar in US'
MiLonza to make delivery vectors for Akouos' gene therapies at Houston plant
MiSanofi wins US approval for 'follow-on' Humalog insulin copy
MiEMA approves production at Samsung Biologics 152,000L plant
DiOxford and MeiraGTx to make AAVs in Central London, UK
DiKite talks audits, training and dry runs across CAR T supply chain
DiAbzena ups and integrates biomanufacturing and conjugation capabilities
DiPlasticell banks on research organisation for cord-blood recruitment
08.12.Biocad bringing biosimilars to North Africa through fill/finish plant
08.12.Three for Friday: Facility news from CSL, Kiadis and ADC Bio
08.12.Gilead buying Cell Design Labs for $567m in further CAR T boost
08.12.Business as usual at Amgen following voluntary evacuation at Cali site
06.12.Standardised single-use tech, the industry's 'holy grail?'
06.12.World's largest single-use plant begins cGMP production
06.12.Regulatory approvals and innovation drives: Cell therapies come of age
05.12.Brexit: Big Pharma calls for 'frictionless trade' and regulatory unity with EU
05.12.US Biological inks antibody labelling deal with Sygnis subsidiary
05.12.Herceptin biosimilar in the US: Ogivri triumphs over GMP setback
01.12.Samsung BioLogics says 180,000L plant is completed but not validated
01.12.Mylan: Reinspection of Biocon plant brings biosimilar confidence
01.12.Brammer Bio: Biologics entering late-stage trials raise capacity concerns, spur $50m investment